New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
13:19 EDTZIOPZiopharm announces results from Phase 1/2 study of Ad-RTS-IL-12
ZIOPHARM Oncology announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. The results from this multicenter study were presented at Melanoma Bridge 2013 Conference at the session "Best Abstracts on News in Immunotherapy", an international conference co-sponsored by Istituto Nazionale Tumori Fondazione, Sidra Medical and Research Center, and the Society for ImmunoTherapy of Cancer that is being held in Naples, Italy."The ability to precisely modulate gene expression at the site of the cancer represents a potential paradigm shift in cancer treatment," said Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations at ZIOPHARM. "We believe the evidence of safety, efficacy and control of gene expression in this study is encouraging and warrants the completion of this trial and the pursuit of a larger Phase 2 clinical trial in patients with advanced melanoma in 2014. We look forward to reporting the full results of this study at a future medical meeting and to initiating later-stage clinical testing in a larger patient population."
News For ZIOP From The Last 14 Days
Check below for free stories on ZIOP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
11:03 EDTZIOPZiopharm presents anti-tumor effects of Ad-RTS-mIL-12
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use